nivolumab,ipilimumab
bms
['hcrn,gu,16,260', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
treatment-free survival can be an important alternative endpoint as presented by michael atkins for the ph2 trial hcrn gu-16 260 cohort a) - this is quite smart esp considering the salvage component of the study. stellar methodology by #gu23
Pharmacogenomics ct, Montreal Heart Institute. Dana-Farber Cancer Institute. Views are my own.